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Background: Polymers have been considered as important materials in fabrication of microstructures for various
medical purposes including drug delivery. This study evaluates polyurethane as material for hollow microstructures
preparation.
Results: Polyurethane microstructures were obtained by interfacial polyaddition combined with spontaneous
emulsification and present slightly acid pH values. Scanning electron microscopy revealed the existence of irregular
shapes and agglomerated microstructures. The material is heat resistant up to 280°C. Good results were recorded
on murine skin tests in case of polyurethane microstructures based on isophorone diisocyanate. Mesenchymal stem
cells viability presents good results for the same sample after 48 hours based on the Alamar Blue test.
Conclusions: The research revealed the reduced noxiousness of this type of microstructures and consequently the
possibility of their use for therapeutic purposes.
Keywords: Polyurethane, Hollow microstructures, Lysine diisocyanate ester, Drug delivery, Zeta potential,
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Many types of microstructures are used as carriers for
therapeutic delivery of active substances. In this field,
molecules such as chemotherapeutic agents can be se-
lectively attached to the microstructure surface or inte-
rior, by covalent conjugation or encapsulation. Another
possibility consists in polymer coatings of the drug in
order to improve its physical-chemical or biological
properties [1,2]. The major classes of nano- and/or
micro-structures used for biomedical applications in-
clude: liposomes, nanoshells, metals and metal oxides,
carbon-based particles, nano- and/or micro-emulsions,
crystals and polymer-based nano- and/or micro-materials
[2,3]. Polymeric nano- and/or micro-structures can be
prepared by dispersion of pre-formed polymers or by
polymerization [4], the second being preferred because it* Correspondence: codrutasoica@umft.ro
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reproduction in any medium, provided the orimplies fewer purifying procedures to eliminate organic
solvents. Polymerization methods implicated in nano-
and/or micro-structure preparation depend on the type
of the monomer and polymerization mechanism, emul-
sion polymerization being probably the most frequently
used [5].
Polyurethanes (PU) consist in hard segments (which al-
ternate diisocyanate and chain-extender molecules) and
amorphous soft, linear diol segments [6]. Within the hard
tissue engineering, much emphasis has been put on deve-
loping lysine-diisocyanate (LDI) based polyurethanes into
load-bearing scaffolds [7]. Bonzani et al. developed a novel
two-component injectable scaffold system [8] which pre-
sented better properties than most other injectable sys-
tems, thus improving osteoblast viability and proliferation.
The use in the therapeutical field imposes the neces-
sity of toxicological evaluation of any new delivery sys-
tem. One US Patent of H. Ralph Snodgrass describes a
method for toxicity evaluation based on mesenchymal
stem cells (MSCs); in his study mammalian MSCs wereral Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SEM images of PU1 microstructures.
Figure 2 SEM images of PU_2 microstructures.
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chemical compositions’ noxiousness [9].
It is well-known that polyurethane materials based
on aromatic diisocyanates suffer an in vivo degradation
leading to carcinogenic aromatic amines [10]. The pre-
sent study avoids this issue by developing three types of
PU microstructures which are based on aliphatic diiso-
cyanates and designed for transdermal drug delivery.
The aim of this research was to obtain microstructures
with a diameter of 600 nm and to test their possible bio-
logical application using preliminary in vitro and in vivo
tests. We studied the influence of raw material structure
on microstructures’ size and we tested their possible no-
xiousness on MSCs and also mouse skin which is more
permeable for penetration of topic compounds. Hairless
mice can be used in such evaluations offering a conve-
nient and reliable model because of their sensitive skin
[11].
Results and discussion
The pH values of microstructures solutions were mea-
sured with a Schott TitroLine by simply plunging the
electrode into the PU aqueous solutions (1:5000 v/v).
The samples present slightly acid pH values (6.61 for
sample PU_1, 6.13 for sample PU_2, and 6.44 for sample
PU_3) due to the characteristics of its components. The
absence of secondary products (amines) is demonstrated
by the weak acid character of suspensions. Beside, these
pH values are appropriate for products intended for cu-
taneous administration [12].
The synthesis of different hollow polymer microstruc-
tures for drug delivery field is nowadays a research topic
of high interest [13,14]. The aim of this study was the
synthesis and testing of PU microstructures with low
toxicity and controlled-sized particles. For drug delivery
systems small size particles are very important in order
to overcome the defence barrier of corneous layer
[15,16], but on the other hand the quantity of encapsu-
lated drug must be taken into consideration. In the PU
microstructures synthesis the presence of an initiator to
form the chains is not necessary. In this case the assem-
bly of polymer chains and the formation of the polymer
shell take place simultaneously, thus it is called an
in-situ polymerization method [17]. In principle, the me-
thod can be adopted in systems where the monomer is
soluble in water while the corresponding polymer is inso-
luble in water at the reaction conditions.
During scanning electron microscopy (SEM) investi-
gations, the existence of microstructure aggregates of
irregular shapes was detected (Figures 1, 2 and 3); the
shape and the size are not influenced by the diisocyanate
used. The microstructures are not spherical in shape
which consequently leads to a poor flowing ability. The
morphology of these PU agglomerates is not characteristicfor a porous-type material which represents an advan-
tage for an intended transdermal vehicle in order to
protect its load. Non-agglomerated microstructures can-
not be successfully synthesized probably due to their low
mass.
Differential scanning calorimetry (DSC) showed that
the degradation is due to a thermooxidative process
(exothermic effect) and takes place at temperatures sig-
nificant higher than the melting point of the polymer
(Figures 4, 5 and 6). As observed, the initial tempera-
tures of the thermooxidative process were closed, as fol-
lows: PU_1 (297°C) > PU_3 (281°C) > PU_2 (276°C).
The final temperatures were: 292 and 296°C for PU_2
and PU_3, respectively. Also, one can notice the absence
of glass transition temperature which is determined for
most polymers; its measurement depends on a crystal-
line transition so its absence usually reveals the predo-
minant amorphous nature of a polymer [18].
Figure 3 SEM images of PU_3 microstructures.
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the diameter of each sample (over 500 nm) which could
be attributed to the particle aggregation process. The
zeta potential values are significant because if all the par-
ticles have a zeta potential more negative than −30 mV
or more positive than +30 mV the dispersion should
remain stable [19]. All this considered, the product
obtained in the second experiment, when isophorone
diisocyanate (IPDI) was used, is regarded as the most
stable.
Noxiousness investigations were carried out on mesen-
chymal stem cells; sources of stem cells described in theFigure 4 The thermal decomposition behaviour of PU_1 microstructuliterature are: bone marrow, peripheric blood, citaferesis
concentrate, umbilical cord and placenta [20]. The main
source for MSCs and haematopoetic cells remains bone
marrow which was also used in our experiments.
All experiments were done in quadruplicate so the ab-
sorbance average of four wells was calculated. Values
thus obtained were introduced into the following for-
mula in order to calculate the reduction level of Alamar
Blue reagent by metabolic activity of cells:
AB%N ¼ O2A1 O1A2ð Þ= R1N2 R2N1ð Þ½ 100
where AB%N is the percentage of reduction of Alamar
Blue reagent compared to the negative control (medium
without cells); O1 represent molar extinction coefficient
(E) for oxidized Alamar Blue at 570 nm; O2 is molar
extinction coefficient (E) for oxidized Alamar Blue at
600 nm; R1 is molar extinction coefficient (E) for
reduced Alamar Blue (red) to 570 nm; R2 is molar ex-
tinction coefficient (E) for reduced Alamar Blue to
600 nm; A1 represent absorbance of tested cells at
570 nm; A2 is absorbance for tested cells at 600 nm; N1
is absorbance of negative control (medium with Alamar
Blue and without cells) to 570 nm; N2 is absorbance of
negative control (medium with Alamar Blue and without
cells) to 600 nm [21]. The results are expressed as the
mean for each quadruplicate culture ± the standard
error.res.
Figure 5 The thermal decomposition behaviour of PU_2 microstructures.
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active indicates a strong metabolic activity and conse-
quently an increased viability and cell proliferation,
while unviable cells produce an oxidized medium (blue).
Previous studies made on silicon-based microparticlesFigure 6 The thermal decomposition behaviour of PU_3 microstructuhave shown that surface properties and chemistry may
influence the adhesion and function of cells in culture
[22].
All samples exhibited metabolic activity as measured by
the detected fluorescence of the Alamar Blue reagent afterres.




Particle size (nm) Zeta Potential
(mV) Mean ± SDMean ± SD Polydispersity index
PU_1 601 ± 142 0.5 18.4 ± 6.2
PU_2 683 ± 242 0.3 27.5 ± 0.4
PU_3 643 ± 201 0.6 13 ± 1.0
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nificantly different between day 1 and 2 (Figures 7 and 8),
but cells were still viable throughout the experiment.
A good result for MSCs viability was recorded for
PU_1 after one day, but we consider MSCs viability after
48 hours to be more important. In this case, the best
value was recorded in case of PU microstructures based
on IPDI. The main conclusion Alamar Blue test pro-
duced was the reduced noxiousness for the studied poly-
meric microstructures.
CD1Nu/Nu (nude mice) present an abnormal hair
growth, due to functional follicles but failed hair growth
and that is why the skin gives a quick response to any ex-
ternal aggressive factor. This mice type was chosen for our
experiment because their skin has the following important
features: it is very sensitive and exhibits a penetration de-
gree a few times higher than human skin [23,24]. The sen-
sitivity of these mice’ skin is an advantage as it can be used
as a parameter characterizing the investigational product
noxiousness. In this study, TweenW20 and diisocyanates
by their specific group (−N = C = O) are known as dan-
gerous substances for human health [25,26], but on the
other hand we have demonstrated above that the polyu-
rethane products did not reveal any toxicity. In the pre-
sent work an excess of polyol was used in order to avoid
the diisocyanates toxicity issue, excess easily removed by
washing and useful to prevent formation of secondary
amine products.Figure 7 The MSCs viability after 24 hours.The transepidermal water loss (TEWL) for the hairless
mice was evaluated by non-invasive techniques for the
characterization of skin changes [27].
Because the application of a new topical compound
could determine important skin parameter changes (e.g.
erythema), the assessment of local haemoglobin and se-
condary melanin (for pigmented animals) content could
be helpful. The Courage-Khazaka instruments are manu-
factured to be generally used in cosmetic tests on human
skin. This is the reason why, previous to this research,
we created a database (unpublished) with mouse skin
parameter values (measured on batches consisting of
four different species of mice, of various ages, with and
without skin lesions). In this study, the evolution of
TEWL values for the four CD1Nu/Nu mice batches (one
blank group and three groups corresponding to the ap-
plied PU microstructures) lies in the range 0–10 g/h/m2
which is specific to skin in very good condition (Figure 9)
[28]. The mice batch where PU_2 was applied shows
a stationary trend over the four weeks so one can con-
clude that IPDI based PU microstructures are appropriate
ingredients for skin application. In other cases TEWL
values slightly increase indicating a reduced damage. In-
creased TEWL values indicates a skin dehydration process
[29] but if the values are not very high above the limit
increased TEWL values do not indicate a certain sign of
noxiousness.
The measured pH average values for CD1Nu/Nu mice
skin are between 6 and 8. One can notice in Figure 10 that
batches 2 and 3 (where PU_2 and PU_3 were applied)
least change their values during the experiment. Measured
pH values indicated no important changes at skin level
[30] leading to the conclusion that application of these PU
formulations maintained the pH of skin.
The erythema, measured by the MexameterWMX 18
probe, is a parameter which slightly increases its values
during different skin testing [31]. When erythema values
change rapidly and significantly it usually is an indicator
Figure 8 The MSCs viability after 48 hours.
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or inflammation [32]. In this experiment the lowest
change of the erythema (local haemoglobin) values was
in case of mice batch 2 (where PU_2 was applied) which
recommends this sample as a transdermal carrier with
the most reduced noxiousness Figures 11 and 12.Conclusions
The interfacial polyaddition technique combined with
spontaneous emulsification is an adequate procedure for
PU microstructures synthesis. The microstructures sus-
pensions present appropriate pH values for products
intended for cutaneous administration. The use of three
different diisocyanates (HMDI, IPDI and LDI) in the
synthesis of PU microstructures was proved as a way to
obtain microstructured polymers which can successfully
candidate as transdermal drug delivery systems. The
comparative analysis of these three diisocyanates per-
formance revealed that the IPDI based microstructuresFigure 9 TEWL evolution ± SEM: TEWL, pH, melanin, and erythema.are the most stable formulations which also present
the best toxicological profile as revealed by MSCs and
in vivo tests.Methods
Synthesis procedure
Lysine diisocyanate ester (LDI) was obtained from
Hangzhou Imaginechem Co., Ltd (China). Mono-ethylene
glycol (MEG) was purchased from Lach-Ner s.r.o.
(Czech Rep.) while 1,4-butanediol (1,4-BD) was purchased
from Carl Roth GmbH (Germany). All the other raw mate-
rials, hexamethylene diisocyanate (HMDI), isophorone dii-
socyanate (IPDI), polyethylene glycol (PEG 200), the solvent
(acetone) and surfactant (TweenW20) were obtained from
Merck (Germany). All substances were used as received.
The polyaddition between diols and diisocyanates for
the polyurethane synthesis follows the reaction from
Scheme 1. Hydroxylic and isocyanate components were
used in a ratio of 1.1 : 1 (w/w) because the hydroxyl
Figure 10 Skin-pH evolution ± SEM.
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product yield from secondary reactions (amines) was
reduced.
The procedure for obtaining PU microstructures by
interfacial polyaddition combined with spontaneous emul-
sification is based on K. Bouchemal experiment [33] and
involves the following steps:
1. Preparation of the organic solution - 1.6 mL
diisocyanate is mixed with 20 mL acetone in a
Berzelius beaker (50 mL) and heated at 40°C.
2. Preparation of the homogeneous aqueous phase -
0.6 mL MEG, 0.6 mL 1,4-BD, 1.2 mL PEG 200 and
1.5 mLTweenW20 are mixed with 40 mL distilled water
in an Erlenmeyer flask (100 mL) and heated at 40°C.
3. Organic phase is injected into the aqueous phase at
40°C under constant magnetic stirring (500 rpm).
Microstructures are formed during this step.Figure 11 Melanin evolution ± SEM.4. Stirring is continued for four hours at 40°C in order
to ensure the maturation of the microstructure walls.
5. Solvent (acetone) as well as a part of water is
removed by slow evaporation in the oven, keeping
the suspension as thin layers (approx. 3 mm) in Petri
dishes at 60°C for 12 hours.
6. Resulting products are purified by three cycles of
centrifugation and dispersion in a mixture water-
acetone (1:1, v/v) in order to eliminate possible
secondary products (amines).
Three experiments were done using the same proced-
ure already described. Three diisocyanate with different
aliphatic chains were chosen to study the effect over the
microstructures size and stability (Table 2).
After the samples were well dried, the solubility
and pH of microstructures were measured at the same
concentration.
Figure 12 Erythema evolution ± SEM.
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PU microstructures’ shape and morphology were exam-
ined using a scanning electron microscope Hitachi
2400S (Hitachi Scientific Ltd., Japan) using a voltage of
10 kV. A thin-layer covering device (Bio-Rad SC 502,
VG Microtech, England) was used to obtain an electric
conductivity to the surface of the samples. The air pres-
sure was between 1.3-13.0 mPa.Differential scanning calorimetry
Thermal analysis was carried out with a Mettler-Toledo
821e instrument between 30–300°C because the ureth-
ane group (−NH-COO-) is stable in this temperature
range [34].Size and surface charge measurements
Particle size, polydisperisity index and zeta potential of
the microstructures were measured using a Zetasizer
Nano ZS (Malvern, UK). Microstructures suspended in
deionized distilled water were added to the sample cu-
vette and the particle size was measured at a 90° fixed
angle and at 25°C. Zeta potential (surface charge) of the
suspended microstructures was also measured using a
Zetasizer Nano ZS. For this, microstructures suspension
was diluted in deionized distilled water and placed in the
electrophoretic cell, and the measurements were done at





PU_1 HMDI, 1.6 0.6
PU_2 IPDI, 1.6 0.6
PU_3 LDI, 1.6 0.6measurements were carried out three times for each
sample.
Mesenchymal stem cells (MSCs) viability tests
Bone marrow was prelevated from patients admitted to
Orthopedics, County Clinical Hospital no. 1 Timisoara,
Romania, who have been submitted for bone surgery.
Previously to prelevation, patients have been informed
about the future use of the biological sample and they
all agreed and signed an Informed Consent according to
the Helsinki Declaration of WHO. The prelevation was
carried out under sterile conditions, using heparinated
syringes.
Approximately 10 mL bone marrow, as source for
MSCs, was diluted 1:1 with phosphate buffer (PBS,
Sigma), centrifuged (1500 rpm) and placed with proli-
feration medium consisting of MEM Alpha medium
(MEM – Alpha; Gibco BRL, Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal calf serum, (FCS,
PromoCell, Heidelberg, Germany), 10 ng/mL fibroblast
growth factor (FGF, Sigma, St. Louis, USA) and 2% mix-
ture of penicillin / streptomycin (10 000 IU/mL, Promo-
Cell, Germany) in plastic culture plate specific for
adherent cell culture (Falcon, 75 cm2, Becton Dickin-
son). Culture plates were incubated at 37°C; medium
was replaced after 48 hours with fresh medium and the
first germ centers with the first colonies of plastic ad-
herent fibroblast cells could be seen using a reversedsis
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(Dulbecco’s Phosphate Buffered saline, Sigma), followed
by a slight rinsing and the confluence cell level was
observed. Medium was replaced every 3–4 days and the
cells were passed when reached 80-90% confluence.
The culture plate was washed with PBS to remove
traces of culture medium and preheated Trypsin-EDTA
0,25% (Sigma) was added in order to act for 2 minutes
on incubated cells after which the microscope was used
to observe the separation of cells. After MSCs were
removed from the plate, trypsin and cells suspension to-
gether with trypsin inactivation medium were centri-
fuged; the supernatant was removed and cells were
counted with a hemocytometer, using 0,4% Trypan Blue
(Sigma), as vital dye. Depending on the number of cells,
they were distributed and reinsaminated in other culture
plates at 10,000 cells/cm2 to ensure optimal prolifera-
tion. MSCs obtained were passed, expanded and further
used in experiments only starting with passages 4–5, at
each passage some cells being frozen for future use.
Long period storage of cells is being done in liquid ni-
trogen, in special tanks.
CellTiter-Blue method was used to estimate the viabil-
ity of cells present in wells plates. It uses resazurin as
color dye to measure the metabolic capacity of cells - an
indicator of cell viability. Viable cells have the ability
to reduce resazurin to resorufin, a fluorescent product.
Unviable cells rapidly lose metabolic capacity, do not re-
duce the dye, and therefore do not generate a fluorescent
signal.
After the cells were counted and trypsinized, it were
seeded in 96 wells plate at a concentration of 7000
cells / well in 150 μL culture medium / well. Thereafter
the cells were allowed to join the incubator at 37°C and
5% CO2 in their proliferation medium for approximately
24 hours. Next day, cell medium was replaced with
medium supplemented with transdermal carrier based on
polyurethane microstructures in concentration 0.1 mg / ml.
All samples were placed in quadruplicate and also were
made four wells with medium with DMSO (1.5 μl) as ne-
gative control and control wells (blank wells or standard)
with normal medium for cell proliferation and wells with
only medium without cells. After 24 and 48 hours of
cells exposure to the mixture of medium with trander-
mal carrier, their viability was tested by CellTiter-Blue
method. It was added to each well of 96 wells plate, a
volume of 15 μl Alamar Blue solution, which represent
10% of the medium volume in each well. Plate was fur-
ther incubated at 37°C for 4–10 hours until there was
observed a color reaction, changing of Alamar Blue rea-
gent from blue color (resazurin) to pink (resorufin). After
incubation the absorbance was measured at 570 nm and
600 nm wavelengths, using a spectrophotometric plate
reader (Bio-Rad, Tokyo, Japan).Animals
CD1Nu/Nu mice of eight weeks were purchased from
Charles River (Sulzfeld, Germany). The work protocol
followed all NIAH - National Institute of Animal Health
rules. Animals were maintained during the experiment
in standard conditions of 12 hours light–dark cycle, food
and water ad libitum, temperature 24°C, humidity above
55%. Mice were divided in four groups (one blank and
one group for each PU microstructure type).
Measurements of skin parameters
In order to observe the changes of the skin parame-
ters, PU microstructures suspensions (2%, w/w) were ap-
plied on the back skin of CD1Nu/Nu mice for four weeks,
three times a week (every other day) (50 μL solution /
application).
After each application, skin parameters determination
was performed within 30 minutes. All the measurements
on the mice skin were carried out according to the pub-
lished guidelines [35] with a Multiprobe Adapter System
(MPA5) from Courage&Khazaka Electronics, Germany,
equipped with a TewameterWTM300 probe, a Skin-pH-
meterWPH905 probe, and a MexameterWMX18 probe.
Measurements with the Skin-pH-meterWPH905 are made
using a probe consisting of a single glass rod containing all
the sensor elements. The planar design of the probe head
allows direct measurement on the skin. The short measu-
ring time avoids occlusive effects on the skin [36].
The melanin values are between 0 and 999 and the
measurement is based on the absorption/reflexion. The
protocol followed the observations on haemoglobin status
(pigmentation and erythema). The device was applied on
most obvious affected areas and maintained on the skin
for 10 seconds [37].
Measurements of TEWL or TEWA (transepidermal
water loss) is an useful tool for revealing and evaluating
skin damage of chemical, physical or pathological origin
as there is a direct proportionality between TEWL in-
crease and the level of damage. This probe records values
between 0–10 g/h/m2 for skin in very good condition,
10–15 g/h/m2 skin in good condition, 15–25 g/h/m2 for
normal skin, 25–30 g/h/m2 for skin in bad condition and
over 30 g/h/m2 for very bad conditions [38].
The data were recorded by the specific soft from the
MexameterWMX18 probe and then expressed as arbi-
trary units. All data were processed as initial and final
measurements values on the same area.Competing interests
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